Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis

  • Glatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL
  • Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched in the US in June 2015, will offer patients a complete range of dosing options
  • A full range of patient support services for Glatopa® is available through GlatopaCare®

Holzkirchen, February 13, 2018 – Sandoz, a Novartis division, today announced the US FDA approval …

/by

Sandoz certified as Top Employer Europe 2018

  • Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings in Europe and Russia
  • The annual, international research undertaken by the Top Employers Institute recognizes leading employers around the world
  • This exclusive certification underlines Sandoz´ commitment to attract and retain the best people from the industry

Holzkirchen, February 1, 2018 – Sandoz, a Novartis division, is proud to announce that it has officially been certified “TOP Employer Europe 2018” for …

/by